本帖最后由 老马 于 2012-1-13 21:20 编辑 ! z6 m8 i8 z' o  ~3 U: e0 e 
% u6 A# C* \" c* L  [ 
爱必妥和阿瓦斯丁的比较 
9 K# b& U7 G# U2 m8 g+ B. j9 |; K
 
6 w" C, w6 m' g1 `) n9 X  N" L! d0 W$ Z 
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/5 v- E' `1 W, l% t4 A 
 
 
$ j. d; J+ b3 P3 v' }
 
 
5 ~' t* `6 b0 nhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ 
9 I5 h$ t9 M2 j# O" H( L================================================== 
/ X  \2 n, B% n5 @! iOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 
! l8 o' p7 H1 |5 sPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.4 l& m( w( |3 u) w3 }  |, B 
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 
( e& a0 |6 s+ Z3 F
 
 |